Related Experiment Videos
[A new antihypertensive: ketanserin]
Rivista Europea Per Le Scienze Mediche E Farmacologiche = European Review for Medical and Pharmacological Sciences = Revue Europeenne Pour Les Sciences Medicales Et Pharmacologiques
|February 1, 1989
Summary
Ketanserin, a novel serotonin antagonist, effectively lowers blood pressure by reducing peripheral resistance. It shows comparable or enhanced efficacy when combined with other antihypertensives, particularly in elderly patients.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Context:
- Hypertension management presents ongoing challenges, necessitating novel therapeutic agents.
- Serotonin receptors play a role in vascular tone and blood pressure regulation.
Purpose:
- To evaluate ketanserin, a selective serotonin S2 and alpha 1 receptor antagonist, as a new antihypertensive agent.
- To compare the efficacy and tolerability of ketanserin with existing antihypertensive drugs.
Summary:
- Ketanserin acts as an arteriolar vasodilator by antagonizing S2 and alpha 1 receptors, leading to decreased peripheral resistance and blood pressure reduction.
- Hypotensive effects were comparable to beta-blockers, diuretics, and calcium antagonists, with combination therapy demonstrating superior efficacy.
- Ketanserin exhibited good tolerability, no pseudo-tolerance, greater effectiveness in elderly patients, and no significant impact on plasma lipid profiles.
Impact:
- Ketanserin offers a promising new therapeutic option for hypertension, especially for elderly individuals.
- Its favorable tolerability and lipid profile may address limitations of current antihypertensive treatments.
- Combination therapy with ketanserin may enhance blood pressure control in a broader patient population.